oleanolic acid has been researched along with glucagon-like peptide 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fussenegger, M; Shao, J; Wang, Y; Xie, M; Xue, S; Yang, L; Ye, H; Yin, J; Yu, Y | 1 |
| Chen, FF; Deng, SL; Tang, L; Wang, JT; Wang, K; Wang, YX; Wu, HS; Xing, SF; Zhang, JQ; Zhang, LX | 1 |
2 other study(ies) available for oleanolic acid and glucagon-like peptide 1
| Article | Year |
|---|---|
A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.
Topics: Animals; Cell Engineering; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Gene Expression Regulation; Gene Regulatory Networks; Genetic Engineering; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Liver Diseases; Male; Mice; Mice, Transgenic; Oleanolic Acid; Synthetic Biology | 2017 |
Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Body Weight; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Enteroendocrine Cells; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Obesity; Oleanolic Acid; Pancreas; Protective Agents | 2017 |